The Neuroscience of Schizophrenia: Brain Regions, Neurotransmitters, and Current Research

Schizophrenia is a severe, chronic psychiatric disorder that affects approximately 1% of the global population, according to estimates from the National Institute of Mental Health (NIMH) and the DSM-5-TR. It is characterized by positive symptoms (hallucinations, delusions, disorganized thinking), negative symptoms (diminished emotional expression, avolition, social withdrawal), and cognitive deficits (impaired working memory, attention, and executive function). While these symptoms have been recognized for over a century, our understanding of the brain mechanisms that produce them has advanced dramatically in the past three decades.

Modern neuroscience has moved away from viewing schizophrenia as a disorder of a single brain region or a single neurotransmitter. Instead, the contemporary scientific consensus frames it as a disorder of brain connectivity — a condition in which the coordinated communication between multiple brain regions and neurotransmitter systems is fundamentally disrupted. This disruption appears to have roots in neurodevelopment, meaning the brain changes associated with schizophrenia likely begin years or even decades before the first psychotic episode.

Understanding the neuroscience of schizophrenia is essential not only for researchers developing new treatments but also for individuals, families, and communities seeking to reduce stigma. Schizophrenia is a brain-based medical condition — not a character flaw, not a consequence of poor parenting, and not a split personality. The science makes this unequivocally clear.

Neuroimaging studies — including structural MRI, functional MRI (fMRI), and positron emission tomography (PET) — have identified several brain regions that show consistent abnormalities in individuals with schizophrenia. No single region tells the whole story; rather, it is the interaction among these regions that appears most relevant.

• Prefrontal Cortex (PFC): The dorsolateral prefrontal cortex (DLPFC) is critical for working memory, executive function, planning, and abstract reasoning. Research consistently shows reduced gray matter volume and decreased activation of the DLPFC during cognitive tasks in individuals with schizophrenia. This finding, sometimes called hypofrontality, is strongly linked to the cognitive deficits and negative symptoms of the disorder.
• Temporal Lobe and Superior Temporal Gyrus: The superior temporal gyrus (STG) is involved in auditory processing and language comprehension. Structural reductions in this region have been associated with auditory hallucinations — one of the hallmark positive symptoms. Functional imaging studies show abnormal activation in the STG during auditory verbal hallucinations, suggesting the brain may be generating internal speech that is misattributed to an external source.
• Hippocampus: The hippocampus plays a central role in memory formation and contextual processing. Reduced hippocampal volume is one of the most replicated structural findings in schizophrenia research. Disrupted hippocampal function may contribute to difficulties distinguishing between internally generated thoughts and external stimuli — a core feature of psychosis.
• Thalamus: The thalamus acts as a sensory relay station, filtering and directing information to the cortex. Abnormalities in thalamic volume and connectivity have been documented in schizophrenia, and dysfunction in thalamocortical circuits may contribute to the sensory processing abnormalities and attentional deficits seen in the disorder.
• Basal Ganglia (Striatum): The striatum, particularly the ventral striatum, is heavily innervated by dopaminergic neurons. Increased dopamine synthesis and release in the striatum is one of the most robust neurochemical findings in schizophrenia, directly tied to positive symptoms such as delusions and hallucinations.
• Anterior Cingulate Cortex (ACC): The ACC is involved in error monitoring, conflict resolution, and motivational processing. Structural and functional abnormalities in the ACC are associated with both cognitive deficits and motivational impairments (avolition) in schizophrenia.

Critically, research increasingly emphasizes that schizophrenia involves disruptions in the white matter tracts connecting these regions — not just the regions themselves. Diffusion tensor imaging (DTI) studies have revealed widespread reductions in white matter integrity, particularly in tracts connecting the frontal and temporal lobes. This supports the conceptualization of schizophrenia as a disconnection syndrome.

For decades, the dopamine hypothesis dominated the neuroscience of schizophrenia. This hypothesis, originally proposed in the 1960s, was based on two key observations: drugs that increase dopamine activity (such as amphetamines) can produce psychotic symptoms, and all effective first-generation antipsychotic medications block dopamine D2 receptors. The hypothesis has been refined considerably since then.

The Revised Dopamine Hypothesis: Modern research supports a more nuanced picture. PET imaging studies have demonstrated increased presynaptic dopamine synthesis capacity and elevated dopamine release in the striatum of individuals with schizophrenia, particularly during acute psychotic episodes. This striatal dopamine excess is most directly linked to positive symptoms. However, the prefrontal cortex appears to have reduced dopaminergic activity, particularly at D1 receptors, which may account for cognitive deficits and negative symptoms. This dual-state model — too much dopamine in subcortical regions, too little in cortical regions — represents the current best understanding of dopamine's role.

Glutamate and the NMDA Receptor Hypothesis: The glutamate hypothesis emerged from the observation that drugs blocking NMDA-type glutamate receptors, such as phencyclidine (PCP) and ketamine, produce a clinical picture remarkably similar to schizophrenia — including positive symptoms, negative symptoms, and cognitive deficits. This is notable because dopamine-enhancing drugs primarily mimic only positive symptoms. Research suggests that NMDA receptor hypofunction, particularly on GABAergic interneurons, may be a core pathological mechanism. When these inhibitory interneurons fail to function properly, it creates a downstream cascade that disrupts cortical circuit function and may drive the excessive subcortical dopamine release described above. This positions glutamate dysfunction as potentially upstream of dopamine abnormalities.

GABA (Gamma-Aminobutyric Acid): Postmortem brain studies have consistently found alterations in GABAergic interneurons in the prefrontal cortex of individuals with schizophrenia, including reduced expression of the enzyme glutamic acid decarboxylase 67 (GAD67) and reductions in the calcium-binding protein parvalbumin. These interneurons are essential for generating gamma oscillations — high-frequency brain waves critical for cognitive processes like working memory and attention. Disrupted gamma oscillations are a well-replicated finding in schizophrenia electroencephalography (EEG) research.

Serotonin: The role of serotonin in schizophrenia is supported by the efficacy of second-generation (atypical) antipsychotics, which have significant serotonin 5-HT2A receptor antagonism. The psychedelic drug LSD, which acts on serotonin receptors, can also produce perceptual disturbances resembling some aspects of psychosis. However, serotonin's precise mechanistic role in schizophrenia remains an active area of investigation.

Schizophrenia is among the most heritable psychiatric disorders. Twin studies estimate heritability at approximately 60–80%, meaning that genetic variation accounts for a substantial portion of the risk. However, the genetics of schizophrenia are extraordinarily complex — there is no single "schizophrenia gene."

Common Genetic Variants: The landmark Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC) genome-wide association study (GWAS) identified over 100 genetic loci associated with schizophrenia risk, and subsequent analyses have expanded this number substantially. Many of these variants implicate genes involved in synaptic function, calcium signaling, and glutamatergic neurotransmission. Notably, the strongest genetic signal maps to the major histocompatibility complex (MHC) region on chromosome 6, and follow-up research identified the complement component 4 (C4) gene within this region. C4 plays a role in synaptic pruning — the developmental process by which the brain eliminates excess synaptic connections during adolescence and early adulthood. Excessive pruning, driven by overactive C4, may contribute to the gray matter loss and cortical thinning observed in schizophrenia.

Rare Genetic Variants: Copy number variants (CNVs) — deletions or duplications of large chromosomal segments — also confer significant risk. The 22q11.2 deletion (associated with velocardiofacial syndrome) carries approximately a 25–30% risk of developing schizophrenia, making it one of the strongest known genetic risk factors for any psychiatric disorder.

The Neurodevelopmental Model: Converging evidence supports the view that schizophrenia is fundamentally a neurodevelopmental disorder. Prenatal risk factors — including maternal infection, nutritional deficiency, and obstetric complications — increase risk. Subtle cognitive, motor, and social abnormalities are often detectable in childhood, years before the onset of psychosis. The typical age of onset in late adolescence to early adulthood coincides with the period of most active synaptic pruning and prefrontal cortical maturation. According to this model, an individual may carry a genetic vulnerability that interacts with environmental stressors across development, culminating in the emergence of frank psychosis when the brain undergoes its final maturational processes.

Epigenetics: Emerging research explores how environmental factors alter gene expression without changing the DNA sequence itself. Epigenetic mechanisms such as DNA methylation and histone modification may help explain how prenatal stress, childhood adversity, and substance use interact with genetic predisposition to increase schizophrenia risk.

One of the most rapidly expanding frontiers in schizophrenia neuroscience is the role of the immune system and neuroinflammation. Several converging lines of evidence point to immune involvement:

• Epidemiological data: Prenatal exposure to infections (influenza, toxoplasmosis) is associated with increased schizophrenia risk in offspring.
• Genetic data: As noted, the strongest GWAS signal for schizophrenia maps to the MHC region, which encodes key immune system proteins.
• Biomarker data: Meta-analyses have found elevated levels of pro-inflammatory cytokines (such as interleukin-6 and tumor necrosis factor-alpha) in the blood and cerebrospinal fluid of individuals with schizophrenia.
• Microglial activation: Microglia are the brain's resident immune cells, and they play a critical role in synaptic pruning during development. PET studies using radioligands that bind to activated microglia have produced mixed but suggestive evidence of increased microglial activation in schizophrenia, particularly in early stages of the illness.

The immune hypothesis does not replace the dopamine or glutamate hypotheses — rather, it may provide a mechanistic bridge. Neuroinflammatory processes can alter glutamate metabolism (through the kynurenine pathway, which converts tryptophan into neuroactive metabolites), disrupt the blood-brain barrier, and modify synaptic plasticity. Research in this area is still evolving, and it remains unclear whether immune abnormalities are a cause, consequence, or parallel process in schizophrenia. Nonetheless, anti-inflammatory agents (such as minocycline and aspirin) are being investigated as adjunctive treatments in clinical trials, with preliminary results showing modest benefits for some symptom domains.

The neuroscience of schizophrenia is advancing on multiple fronts, driven by increasingly powerful research tools and interdisciplinary collaboration.

Polygenic Risk Scores (PRS): Researchers are developing polygenic risk scores that aggregate the effects of thousands of genetic variants to estimate an individual's overall genetic liability for schizophrenia. While PRS are not yet clinically useful for diagnosis — their predictive power at the individual level remains modest — they are valuable for stratifying research populations and studying gene-environment interactions.

Computational Psychiatry: This emerging field uses mathematical models to understand how disruptions in specific neural computations (such as predictive coding or reinforcement learning) give rise to the symptoms of schizophrenia. For example, some models propose that psychosis reflects a failure of predictive processing — the brain's normal mechanism for generating expectations about sensory input. When the brain assigns excessive weight to prediction errors, ordinary stimuli may be interpreted as highly salient, potentially contributing to delusion formation.

Neuroimaging Biomarkers: Large-scale consortia such as the ENIGMA Schizophrenia Working Group are pooling neuroimaging data from thousands of participants to identify reliable brain-based biomarkers. Findings include widespread cortical thinning, subcortical volume reductions (particularly in the hippocampus and amygdala), and enlarged lateral ventricles. These structural signatures, combined with functional connectivity patterns, may eventually contribute to earlier identification and treatment monitoring.

Novel Pharmacological Targets: The limitations of current antipsychotic medications — which primarily target dopamine D2 receptors and are most effective for positive symptoms — have driven the search for drugs acting on alternative mechanisms. Muscarinic acetylcholine receptor agonists (such as xanomeline-trospium, which received FDA approval in 2024) represent the first truly novel mechanism of action for schizophrenia treatment in decades. Other targets under investigation include metabotropic glutamate receptors (mGluR2/3), glycine transporter inhibitors (to enhance NMDA receptor function), and trace amine-associated receptor 1 (TAAR1) agonists.

Early Intervention and the Prodrome: Neuroscience research is increasingly focused on the clinical high-risk (CHR) or prodromal stage — the period before the first full psychotic episode when subtle symptoms and functional decline begin. Identifying neurobiological markers that predict which high-risk individuals will convert to full psychosis is a major research priority. If reliable biomarkers can be identified, it may become possible to intervene earlier and potentially alter the trajectory of the illness.

While the neuroscience of schizophrenia has not yet yielded a cure, it has fundamentally shaped how the disorder is understood and treated in clinical practice.

Pharmacotherapy: The mechanism of action of antipsychotic medications is grounded in the dopamine hypothesis. First-generation (typical) antipsychotics like haloperidol primarily block D2 receptors. Second-generation (atypical) antipsychotics like clozapine, risperidone, and olanzapine affect both dopamine and serotonin receptors, which may contribute to their somewhat broader efficacy profile. Clozapine remains the gold-standard treatment for treatment-resistant schizophrenia, though its precise mechanism of superiority is still not fully understood. The approval of xanomeline-trospium (a muscarinic agonist combination) in 2024 marked the first major mechanistic departure from D2 antagonism, validating decades of research into cholinergic pathways.

Cognitive Remediation: Understanding the neurocognitive deficits in schizophrenia — and their basis in prefrontal cortical dysfunction — has led to the development of cognitive remediation therapy (CRT). CRT uses targeted cognitive exercises to improve working memory, attention, and executive function. Neuroimaging studies suggest CRT can produce measurable changes in prefrontal activation patterns, supporting the idea that targeted intervention can promote neural plasticity even in schizophrenia.

Neurostimulation: Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are being investigated as treatments for specific symptom domains. For example, low-frequency TMS applied to the left temporoparietal junction has shown promise for reducing auditory hallucinations in some studies, based on the finding of abnormal activation in this region during hallucinations.

Integrated Care: The neuroscience underscores that schizophrenia is a multisystem disorder affecting cognition, motivation, social functioning, and perception. This supports the clinical approach of coordinated specialty care (CSC) programs for first-episode psychosis, which combine medication management, psychotherapy, family education, supported employment, and case management. Research, including the NIMH-funded RAISE study, has demonstrated that CSC programs improve outcomes compared to treatment as usual.

Despite significant scientific advances, several persistent misconceptions about schizophrenia continue to circulate in public discourse.

• "Schizophrenia means split personality." This is perhaps the most widespread and harmful misconception. Schizophrenia has nothing to do with dissociative identity disorder (previously called multiple personality disorder). The term "schizophrenia," coined by Eugen Bleuler in 1911, refers to a splitting of mental functions — such as thought, emotion, and behavior becoming disconnected — not a splitting of personality into multiple identities.
• "Schizophrenia is caused by bad parenting." Mid-20th-century theories blamed "schizophrenogenic mothers" for causing the illness. This concept has been thoroughly debunked. While family environment can influence the course of the disorder (expressed emotion research demonstrates this), schizophrenia is fundamentally a brain-based condition with strong genetic underpinnings.
• "It's all about dopamine." While dopamine dysregulation is a central feature, schizophrenia involves disruptions across multiple neurotransmitter systems (glutamate, GABA, serotonin, acetylcholine), widespread structural brain changes, immune system abnormalities, and neurodevelopmental processes. Reducing it to a single neurotransmitter oversimplifies a complex disorder.
• "Brain scans can diagnose schizophrenia." Despite significant progress in identifying group-level neuroimaging differences, no brain scan can currently diagnose schizophrenia in an individual patient. Diagnosis remains clinical, based on the criteria outlined in the DSM-5-TR (Schizophrenia Spectrum and Other Psychotic Disorders, diagnostic code 295.90 / F20.9). Brain imaging is used in research and sometimes clinically to rule out other conditions (such as tumors or encephalitis), but not to confirm a schizophrenia diagnosis.
• "People with schizophrenia are inherently violent." Neuroscience research does not support this stereotype. While some studies show modestly elevated rates of violence, these are largely attributable to co-occurring substance use, treatment nonadherence, and environmental factors. Individuals with schizophrenia are far more likely to be victims of violence than perpetrators.
• "Schizophrenia is untreatable." This is false. While schizophrenia is a chronic condition that often requires lifelong management, many individuals achieve significant symptom reduction and functional recovery with appropriate treatment. Neuroscience-informed treatments continue to improve outcomes.

The neuroscience of schizophrenia has made remarkable progress, but significant gaps remain. Here is an honest accounting of where the field stands:

Well-established findings:

• Schizophrenia involves measurable structural brain changes, including cortical gray matter reductions, hippocampal volume loss, and ventricular enlargement.
• Elevated striatal dopamine synthesis and release are consistently associated with positive symptoms.
• NMDA receptor hypofunction on GABAergic interneurons is a plausible upstream mechanism contributing to cortical circuit dysfunction.
• The disorder has strong genetic underpinnings, with polygenic architecture and contributions from both common and rare variants.
• Synaptic pruning abnormalities, potentially involving complement system genes, may play a causal role.
• Schizophrenia follows a neurodevelopmental trajectory, with brain changes preceding symptom onset by years.

Areas of active investigation and uncertainty:

• The precise causal relationship between glutamate, dopamine, and GABA abnormalities remains debated. Which disruption comes first?
• The role of neuroinflammation is promising but not yet definitively established as causal.
• No reliable individual-level biomarker exists for diagnosis, prognosis, or treatment selection.
• The mechanisms underlying treatment resistance — and clozapine's unique efficacy — are poorly understood.
• It remains unclear whether schizophrenia represents a single disorder with variable expression or a cluster of biologically distinct conditions sharing a clinical phenotype.
• How environmental risk factors (cannabis use, urbanicity, childhood trauma, migration) interact with genetic vulnerability at the neurobiological level requires further elucidation.

The field is converging on a model in which schizophrenia arises from the interaction of polygenic risk, environmental exposures across development, and resulting disruptions in synaptic function, neurotransmitter balance, and brain connectivity. This model is complex, but it reflects the genuine complexity of the disorder.

If you or someone you know is experiencing symptoms that may be consistent with schizophrenia — such as hearing voices that others do not hear, holding beliefs that seem unfounded to others, significant difficulty organizing thoughts, marked social withdrawal, or a noticeable decline in daily functioning — it is important to seek a professional evaluation promptly.

Early intervention matters. Research consistently demonstrates that the duration of untreated psychosis (DUP) — the time between the onset of psychotic symptoms and the initiation of treatment — is one of the strongest predictors of long-term outcomes. Shorter DUP is associated with better treatment response, greater functional recovery, and reduced cognitive decline. This makes early recognition and treatment a clinical priority.

A qualified mental health professional — such as a psychiatrist, clinical psychologist, or psychiatric nurse practitioner — can conduct a comprehensive evaluation that includes a detailed clinical interview, assessment of symptom history, consideration of family history, and exclusion of other medical or psychiatric conditions that can mimic psychosis (including substance-induced psychotic disorders, mood disorders with psychotic features, and neurological conditions).

If you are in crisis, contact the 988 Suicide and Crisis Lifeline (call or text 988 in the United States) or go to your nearest emergency department. Psychosis is a medical emergency when it involves imminent risk to safety.